Registered outcomes15

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 15 of 15

List	Outcome	Time frame	Description
Primary	Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)	52 Weeks	Change from baseline in the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) total score at Week 26 and Week 52. Possible scores range from 0 to 18; higher scores represent greater dementia impairment (worse outcome).
Secondary	Alzheimer's Disease Assessment Scale-Cognitive Subscale 13-item (ADAS-Cog13)	52 Weeks	Change from baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale 13-item (ADAS-Cog13) score at Week 26 and Week 52. Possible scores range from 0 to 85; higher scores represent worse cognitive function (worse outcome).
Secondary	Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)	52 Weeks	Change from baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) score at Week 26 and Week 52. Possible scores range from 0 to 78; higher scores represent better daily function (better outcome).
Secondary	15-item Geriatric Depression Scale (GDS-15)	52 Weeks	Change from baseline in the 15-item Geriatric Depression Scale (GDS-15) score at Week 26 and Week 52. Possible scores range from 0 to 15; higher scores represent more severe depressive symptoms (worse outcome).
Secondary	Mini-Mental State Examination (MMSE)	52 Weeks	Change from baseline in the Mini-Mental State Examination (MMSE) score at Week 26 and Week 52. Possible scores range from 0 to 30; higher scores represent better global cognitive function (better outcome).
Secondary	Plasma p-tau181	52 Weeks	Change from baseline in plasma p-tau181 concentration at Week 26 and Week 52.
Secondary	Plasma p-tau217	52 Weeks	Change from baseline in plasma p-tau217 concentration at Week 26 and Week 52.
Secondary	Plasma p-tau231	52 Weeks	Change from baseline in plasma p-tau231 concentration at Week 26 and Week 52.
Secondary	Plasma Aβ42	52 Weeks.	Change from baseline in plasma Aβ42 concentration at Week 26 and Week 52.
Secondary	Plasma Aβ40	52 Weeks	Change from baseline in plasma Aβ40 concentration at Week 26 and Week 52.
Secondary	Plasma Aβ42/Aβ40 Ratio	52 Weeks	Change from baseline in plasma Aβ42/Aβ40 ratio at Week 26 and Week 52.
Secondary	Plasma Glial Fibrillary Acidic Protein (GFAP)	52 Weeks	Change from baseline in plasma Glial Fibrillary Acidic Protein (GFAP) concentration at Week 26 and Week 52.
Secondary	Plasma Neurofilament Light Chain (NfL)	52 Weeks	Change from baseline in plasma Neurofilament Light Chain (NfL) concentration at Week 26 and Week 52.
Secondary	Brain Aβ-PET Centiloid (CL)	52 Weeks	Change from baseline in brain amyloid-beta PET quantified Centiloid (CL) value at Week 26 and Week 52. Higher Centiloid values indicate greater amyloid-beta burden (worse amyloid pathology).
Secondary	Adverse Events (AEs) and Serious Adverse Events (SAE	52 Weeks	Incidence, frequency, and severity of adverse events (AEs) and serious adverse events (SAEs) from baseline through Week 52.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07905352/registered

API reference For AI assistants